Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of methotrexate powder cas 59-05-2 in China. Welcome to wholesale bulk high quality methotrexate powder cas 59-05-2 for sale here from our factory. Good service and reasonable price are available.
Methotrexate powder is a potent medication primarily used in the management of various autoimmune conditions and certain forms of cancer. Belonging to the class of drugs known as antimetabolites, it disrupts DNA synthesis and cell proliferation, thereby exerting its therapeutic effects.In autoimmune diseases such as rheumatoid arthritis, psoriasis, and certain types of vasculitis, it helps to reduce inflammation and slow down disease progression by modulating the immune system's overactive response. Administered orally or via injection, depending on the treatment plan, it can significantly improve symptoms and enhance quality of life for patients.
For the treatment of cancer, particularly certain types of leukemia, lymphoma, and breast cancer, it acts as a chemotherapy agent, targeting rapidly dividing cancer cells. However, its use in oncology often requires careful dosing and monitoring due to its potential for toxicity and side effects.
 |
 |
|
Chemical Formula |
C16H15ClO6 |
|
Exact Mass |
338.06 |
|
Molecular Weight |
338.74 |
|
m/z |
338.06 (100.0%), 340.05 (32.0%), 339.06 (17.3%), 341.06 (5.5%), 340.06 (1.4%), 340.06 (1.2%) |
|
Elemental Analysis |
C, 56.73; H, 4.46; Cl, 10.47; O, 28.34 |
Antimetabolite Applications
Inhibition of Dihydrofolate Reductase (DHFR)
Methotrexate powder acts as an antimetabolite by inhibiting the enzyme dihydrofolate reductase (DHFR). This enzyme is crucial in the conversion of dihydrofolate (DHF) to tetrahydrofolate (THF), a vital cofactor in the synthesis of purines, thymidylate, and certain amino acids.
By inhibiting DHFR, methotrexate prevents the formation of THF, thereby disrupting the synthesis of DNA, RNA, and proteins essential for cell growth and division.
Suppression of DNA Synthesis
As a result of inhibiting THF production, methotrexate disrupts the one-carbon transfer reactions necessary for the synthesis of nucleotides, ultimately inhibiting DNA synthesis. This effect is particularly pronounced during the S phase of the cell cycle, when DNA replication occurs.
Antitumor Activity
Widely used as an antineoplastic agent in the treatment of various cancers, including acute lymphoblastic leukemia, breast cancer, head and neck cancer, and others. Its ability to inhibit DNA synthesis leads to the arrest of cancer cell growth and proliferation.
Antifolate Applications
Folate Antagonism
Functions as an antifolate by antagonizing the actions of folic acid (vitamin B9). Folic acid is essential for the synthesis and metabolism of nucleotides and amino acids, making it a critical component of cellular growth and division.
By blocking the conversion of folic acid to its active form, THF, methotrexate disrupts the folate cycle and impairs the synthesis of nucleic acids and proteins.
Treatment of Autoimmune Diseases
In addition to its antitumor activity, it is also used as an immunosuppressant in the treatment of autoimmune diseases such as rheumatoid arthritis.
By inhibiting the proliferation of immune cells, methotrexate helps to reduce inflammation and alleviate symptoms associated with these diseases.
Combination Therapy
Often used in combination with other drugs to enhance its therapeutic effects. For example, in the treatment of cancer, methotrexate may be combined with other chemotherapeutic agents to target multiple pathways involved in cancer cell growth and survival.
in Cancer Treatment
Methotrexate primarily functions by inhibiting dihydrofolate reductase, an enzyme crucial for converting dihydrofolate to tetrahydrofolate (THF). THF is a vital cofactor in the synthesis of nucleotides, which are building blocks of DNA and RNA. By blocking this conversion, methotrexate disrupts the production of nucleotides, thereby inhibiting DNA synthesis and ultimately suppressing cancer cell growth and proliferation.
Acute Lymphoblastic Leukemia (ALL)
Methotrexate is a key component in the treatment of ALL, often used in combination with other chemotherapeutic agents such as vincristine and prednisone. This combination, known as the Vincristine-Adriamycin-Dexamethasone (VAD) regimen, has shown significant efficacy in ALL patients.
It is also employed in the treatment of various solid tumors, including breast cancer, lung cancer, head and neck cancer, and gastrointestinal cancers. The dosage and administration schedule vary depending on the specific cancer type and stage.
Choriocarcinoma and Gestational Trophoblastic Disease
Methotrexate powder is highly effective in treating choriocarcinoma and other gestational trophoblastic diseases, which are rare but aggressive forms of cancer that arise from placental tissue.
It is used in the treatment of both Hodgkin's and non-Hodgkin's lymphomas, often in combination with other drugs like doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD regimen).
In certain cases, high-dose methotrexate therapy with leucovorin rescue (HD-MTX/CFR) is administered to patients with refractory or relapsed cancers. This approach involves administering a high dose of methotrexate followed by leucovorin to reduce toxicity and enhance the drug's efficacy.
autoimmune diseases
Rheumatoid Arthritis (RA)
Primary Use: MTX is a cornerstone treatment for RA, particularly in moderate to severe cases. It helps to reduce inflammation, slow disease progression, and improve functional outcomes.
Mechanism: By inhibiting T and B cell activity and reducing immune mediators, MTX exerts its anti-inflammatory and immunosuppressive effects.
Applications: MTX is also used in the treatment of juvenile idiopathic arthritis, psoriatic arthritis, Felty's syndrome, and skin vasculitis associated with RA.
Efficacy: Its efficacy has been well-established in these conditions, often leading to improved patient outcomes.
Systemic Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)
Methotrexate (MTX) powder serves as a crucial adjunct therapeutic agent for the clinical management of Systemic Lupus Erythematosus (SLE), playing an irreplaceable auxiliary role in standardized SLE treatment regimens. For most mild-to-moderate SLE patients, conventional treatment schemes including glucocorticoids and hydroxychloroquine can effectively control basic symptoms, yet a considerable number of patients suffer from persistent rash, recurrent arthritis, mild serositis and other clinical manifestations that cannot be fully relieved by first-line drugs.
In addition, some patients are intolerant to high-dose glucocorticoids or face the risk of recurrent disease during hormone tapering. Under these clinical scenarios, low-to-medium dose methotrexate can be added as combination therapy. It exerts potent anti-inflammatory and immunosuppressive effects by inhibiting folate metabolism and reducing the proliferation of abnormal immune cells, effectively improving refractory joint pain, cutaneous lesions and chronic inflammatory responses in SLE patients, while assisting in reducing the cumulative dosage of glucocorticoids and lowering the incidence of hormone-related adverse reactions such as osteoporosis and hyperglycemia. It is particularly suitable for SLE patients with predominant articular and cutaneous manifestations who respond poorly to traditional single-drug treatments.
Systemic Sclerosis (SSc)
Systemic Sclerosis (SSc) is a refractory systemic autoimmune disease characterized by diffuse skin fibrosis, vascular lesions and multi-organ interstitial damage, with limited clinical treatment options and poor long-term prognosis. Multiple clinical studies and clinical practice guidelines have confirmed that Methotrexate has significant clinical value in the treatment of SSc and can effectively slow down the overall progression of the disease.
For early-stage diffuse cutaneous systemic sclerosis patients with active skin thickening, swelling and induration, MTX can inhibit the abnormal proliferation of fibroblasts and excessive deposition of extracellular matrix, thereby alleviating skin fibrosis and improving skin hardness and joint mobility.Meanwhile, it can suppress chronic systemic inflammatory responses, reduce inflammatory damage to small blood vessels throughout the body, and delay the progression of microvascular lesions and interstitial lesions of internal organs. For patients with early active SSc without severe visceral organ failure, standardized MTX monotherapy or combined with low-dose glucocorticoids can significantly improve clinical symptoms, stabilize disease conditions, and reduce the risk of rapid progression of skin and organ fibrosis.
Inflammatory Myopathies
Inflammatory myopathies, represented by dermatomyositis and polymyositis, are a group of autoimmune inflammatory diseases targeting skeletal muscle, clinically manifested as symmetric proximal muscle weakness, muscle pain, and accompanied by characteristic cutaneous lesions (in dermatomyositis) and elevated muscle enzymes. Glucocorticoids are the first-line therapeutic drugs, but a large proportion of patients develop refractory disease with ineffective hormone monotherapy, or suffer from repeated disease flares during hormone reduction, and some severe patients cannot achieve disease remission even with high-dose glucocorticoids.
Methotrexate powder is a classic and preferred immunosuppressant for such refractory and severe inflammatory myopathies. It can specifically inhibit the immune-mediated inflammatory infiltration of muscle tissues, reduce muscle fiber necrosis and inflammatory exudation, effectively lower serum creatine kinase levels, improve muscle strength and relieve myalgia symptoms. In addition, MTX can significantly reduce the maintenance dose of glucocorticoids, reduce the incidence of long-term hormone complications, and greatly improve the long-term treatment efficacy and quality of life of patients with severe or recurrent inflammatory myopathies.
Autoimmune Skin Diseases
Psoriasis
Methotrexate is one of the most classic, safe and well-established systemic therapeutic drugs for moderate to severe psoriasis, and has been included in the treatment guidelines for psoriasis at home and abroad for a long time. It is widely applicable to various clinical subtypes of progressive and refractory psoriasis, including common plaque-type psoriasis, acute guttate psoriasis, and severe erythrodermic psoriasis and pustular psoriasis.
For mild psoriasis, topical medications and phototherapy are the main treatments, while moderate and severe psoriasis with large lesion area, obvious inflammatory infiltration and recurrent onset require systemic immunosuppressive intervention.MTX inhibits the excessive proliferation of epidermal keratinocytes and blocks the abnormal activation of inflammatory immune pathways in skin lesions, thereby rapidly reducing skin erythema, scaling and infiltration swelling. Long-term standardized low-dose MTX treatment can effectively control disease recurrence, reduce lesion coverage, and significantly improve patients' skin appearance and clinical symptoms. With definite curative effect and controllable adverse reactions, it remains a core conventional drug for the systemic treatment of moderate to severe psoriasis.
Autoimmune Bullous Diseases
Autoimmune bullous diseases represented by pemphigus vulgaris and bullous pemphigoid are a group of severe autoimmune skin diseases caused by autoantibodies targeting skin and mucosal basement membrane components, clinically characterized by blister formation, erosion and exudation of skin and mucous membranes, which are prone to infection and affect patients' daily life. Glucocorticoids are the first-line drugs for controlling acute disease conditions, but long-term high-dose hormone use is accompanied by multiple systemic adverse reactions, and some patients have unstable disease control after hormone reduction.
Methotrexate is commonly used as an important adjunctive therapy combined with corticosteroids for such diseases. It assists in suppressing abnormal autoimmune responses, reducing the production of pathogenic autoantibodies, accelerating the healing of skin and mucosal erosions and blisters, and stabilizing disease conditions. More importantly, combined application with MTX can effectively reduce the required dosage and course of glucocorticoids, avoid hormone dependence and severe hormone-related complications, and is especially suitable for elderly patients, patients with hormone intolerance and recurrent autoimmune bullous disease patients.
Vascular Inflammatory Diseases
Vasculitis
Vasculitis is a heterogeneous group of inflammatory diseases centered on vascular wall inflammatory damage and necrosis, involving blood vessels of different calibers throughout the body, and can cause ischemic damage to multiple organs and systems. Methotrexate is a classic conventional immunosuppressant widely used in the treatment of various primary systemic vasculitides, including Wegener's granulomatosis (granulomatosis with polyangiitis), giant cell arteritis, Takayasu's arteritis and other common types of vasculitis.
It can be used for mild-to-moderate active vasculitis as monotherapy, or as maintenance combined therapy for severe vasculitis after remission induced by high-dose hormones and immunosuppressants.
Mechanism
The core therapeutic value of MTX in vascular inflammatory diseases stems from its dual effects of efficient anti-inflammation and targeted inhibition of immune-mediated vascular damage.
On the one hand, MTX inhibits the synthesis of inflammatory cytokines such as tumor necrosis factor and interleukin, blocks the cascade amplification of vascular inflammatory responses, reduces inflammatory cell infiltration into the vascular wall, and relieves vascular wall edema, exudation and inflammatory necrosis.On the other hand, it regulates the abnormal hyperactive immune system, inhibits autoimmune-mediated vascular immune damage, prevents vascular stenosis, occlusion and aneurysm formation caused by long-term vascular inflammation, effectively controls disease activity, delays vascular lesion progression, reduces the recurrence rate of vasculitis, and decreases the risk of organ ischemic complications, making it a safe and reliable long-term therapeutic option for various vasculitis diseases.
Methotrexate powder (MTX) is a classic anti metabolic drug that has become an important medication for cancer chemotherapy, autoimmune diseases (such as rheumatoid arthritis), and certain skin diseases (such as psoriasis) since its discovery in the 1940s. Its discovery and development represent important milestones in modern medicinal chemistry and pharmacology, not only advancing the research of anti-tumor drugs, but also opening up new avenues for immunomodulatory therapy.
The discovery of methotrexate is closely related to the study of folic acid. Folic acid is a B-complex vitamin (vitamin B9), first discovered by British scientist Lucy Wills in 1931, who observed that yeast extract could prevent gestational megaloblastic anemia.
In 1941, American scientists Herschel K. Mitchell and others isolated folic acid from spinach leaves and determined its chemical structure. Folic acid is converted into tetrahydrofolate (THF) in the human body, which participates in DNA synthesis, amino acid metabolism, and cell proliferation. Due to the rapid proliferation of cancer cells and their dependence on folate metabolism, scientists have begun to study how to interfere with folate metabolism to inhibit tumor growth.
In the 1940s, scientists discovered that certain folate analogues could competitively inhibit folate metabolism, thereby preventing cancer cell proliferation.
In 1947, American pharmacologist Sidney Farber and his team discovered that aminopterin (4-aminofolate) could temporarily alleviate leukemia symptoms while studying acute leukemia in children at Harvard Medical School. This is the first drug in history to be successfully used for cancer chemotherapy, marking the beginning of the era of chemotherapy.
Aminopterin has strong toxicity and poor patient tolerance. In order to search for safer derivatives, American chemist Yellapragada Subbarow and his team structurally modified aminopterin in Lederle Laboratories and ultimately synthesized Methotrexate (MTX), also known as 4-amino-10-methylfolate, in 1948. Compared with aminopterin, methotrexate has lower toxicity, but its anti-tumor activity is still significant.
In the 1950s, scientists further elucidated the mechanism of action of methotrexate. It interferes with the purine and thymidine required for DNA synthesis by inhibiting dihydrofolate reductase (DHFR) and preventing the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). Due to the rapid proliferation of cancer cells and high demand for folate, methotrexate can selectively inhibit tumor growth.
In 1953, Roy Hertz and Min Chiu Li from the National Cancer Institute (NCI) reported for the first time that methotrexate successfully cured choriocarcinoma, the first solid tumor in human history to be cured through chemotherapy. This breakthrough has made methotrexate an important drug for cancer treatment.
In the 1960s, researchers discovered that methotrexate not only had anti-tumor effects, but also could inhibit excessive activation of the immune system.
In 1964, American doctor Edmund Dubois first attempted to treat psoriasis with low-dose methotrexate and achieved significant results. Subsequently, in the 1980s, methotrexate was widely used for the treatment of rheumatoid arthritis (RA), becoming the gold standard for "disease modifying antirheumatic drugs (DMARDs)".
FAQ
Is methotrexate available in liquid form?
+
-
Methotrexate is available on prescription only. It comes as tablets, a liquid that you swallow, and pre-filled injection pens or syringes that you inject into your skin. Your specialist doctor may recommend injections if the tablets or liquid are not working for you.
What is methotrexate used for?
+
-
What is this medication? METHOTREXATE (METH oh TREX ate) treats autoimmune conditions, such as arthritis and psoriasis. It works by decreasing inflammation, which can reduce pain and prevent long-term injury to the joints and skin. It may also be used to treat some types of cancer.
Hot Tags: methotrexate powder cas 59-05-2, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, filgotinib, Methylprednisolone Hemisuccinate CAS 2921 57 5, 3 DiMethylaMino 1 4 Methoxyphenyl prop 2 en 1 one CAS 18096 70 3, Sapropterin Hydrochloride, articaine hydrochloride powder, phenacetin crystal